The Patent Finder

Terms ending in 2034

Acceleron Pharma Inc.

Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,809,637Transforming Growth Factor Beta Receptor II Fusion Polypeptides
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 10,316,076Transforming Growth Factor-Beta Receptor Type II Fusion Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 10,981,973Methods of Treating a Sclerotic Disorder by Administering a Transforming Growth Factor Beta Receptor Type II Fusion Polypeptide
In force
 · High confidence
Acceleron Pharma Inc.In forceHigh confidence
US 11,008,377Methods of Treating a Fibrotic Disorder by Administering Transforming Growth Factor Beta Receptor II Fusion Polypeptides
In force
 · Medium confidence
Acceleron Pharma Inc.In forceMedium confidence
US 11,590,201Endoglin Peptides to Treat Fibrotic Diseases
In force
 · High confidence
Acceleron Pharma, Inc.In forceHigh confidence
US 10,682,392Methods for Treating Pulmonary Hypertension with a Tgf-Beta Type II Receptor-Fc Fusion Protein
In force
 · High confidence
The Brigham and Women's Hospital, Inc.In forceHigh confidence
US 11,951,156Methods for Treating Pulmonary Hypertension with a Ligand Binding Domain of a Tgf-Beta Type II Receptor
In force
 · High confidence
The Brigham and Women's Hospital, Inc.In forceHigh confidence
US 12,678,483Methods for Treating Pulmonary Disease with a Ligand Binding Domain of a Tgf-Beta Type II Receptor
In force
 · High confidence
The Brigham and Women's Hospital, Inc.In forceHigh confidence
8 of 8 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited